Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
|Articles|April 22, 2016
Unraveling the Mystery of Changes to USP
The Pharmacy Compounding Accreditation Board, Attentus Medical Sales Inc, and VGM and Associates will host a series of free webinars to discuss the implications of the recently released hazardous drug safety standards by the United States Pharmacopeial Convention USP .
Advertisement
The Pharmacy Compounding Accreditation Board, Attentus Medical Sales Inc, and VGM and Associates will host a series of free webinars to discuss the implications of the recently released hazardous drug safety standards by the United States Pharmacopeial Convention USP <800>.
Advertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
3
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
4
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
5